Product Approval Breathes New Life Into Boan Biotech IPO
The biosimilar drug maker was approved to sell its second new product in China last month as it applies to list in Hong KongKey Takeaways:Boan Biotechnology has filed for a…
Recent Articles
RELATED ARTICLES
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK -
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
